Clinical Trial Update: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating atezolizumab in combination with enzalutamide for metastatic castration-resistant prostate cancer after AR pathway inhibitor and taxane…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 3 | Status: COMPLETED | Results posted: 2021-04-30